title: Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout.
abstract: Since the discovery of the inflammasome, interleukin 1 production has been found to be integral in the pathophysiology of gout. Interleukin 1 inhibition by Anakinra has been shown to effective for the treatment of gout. We report three cases of resistant chronic tophaceous gout who responded to anakinra subcutaneous injections on an intermittent basis.
authors.affiliation: Sir Charles Gairdner Hospital, Rheumatology, Perth, Western Australia, Australia. aptran7@msn.com
authors.forename: Ai P
authors.initials: AP
authors.lastname: Tran
authors.forename: Jack
authors.initials: J
authors.lastname: Edelman
mesh_terms: D000208:Acute Disease; D000368:Aged; D000493:Allopurinol / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D002908:Chronic Disease; D003078:Colchicine / Q000627:therapeutic use; D004351:Drug Resistance / Q000187:drug effects; D006073:Gout / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D006074:Gout Suppressants / Q000627:therapeutic use*; D006801:Humans; D007279:Injections, Subcutaneous; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use*; D007375:Interleukin-1 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D006074:Gout Suppressants; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D000493:Allopurinol; D003078:Colchicine